Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Classical hematology 1

Conditions

Hemophilia A 2Lymphoma, Follicular 1

Interventions

Rituximab 168Cyclophosphamide 142Peripheral Blood Stem Cell Transplantation 84fludarabine phosphate 68Filgrastim 64Etoposide 63Radiotherapy 55Vincristine 47Prednisone 45Mycophenolic Acid 44Melphalan 40Whole-Body Irradiation 39Cyclosporine 39Busulfan 39Tacrolimus 36Doxorubicin 34Cytarabine 33Lenalidomide 29Carmustine 28Antilymphocyte Serum 28Methotrexate 27Methylprednisolone 26Bortezomib 26Bendamustine Hydrochloride 26sargramostim 21ibritumomab tiuxetan 20obinutuzumab 19ibrutinib 18fludarabine 18Dexamethasone 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, Follicular × Factor VIII × Clear all
NCT00037544 2008-04-22

Study Evaluating ReFacto AF in Severe Hemophilia A

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 3 Completed
Classical hematologyLymphoid

Hemophilia A, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡